Literature DB >> 21414605

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

Thomas Hansen1, Andrés Ingason, Srdjan Djurovic, Ingrid Melle, Mogens Fenger, Omar Gustafsson, Klaus D Jakobsen, Henrik B Rasmussen, Sarah Tosato, Marcella Rietschel, Josef Frank, Mike Owen, Chiara Bonetto, Jaana Suvisaari, Johan Hilge Thygesen, Hannes Pétursson, Jouko Lönnqvist, Engilbert Sigurdsson, Ina Giegling, Nick Craddock, Michael C O'Donovan, Mirella Ruggeri, Sven Cichon, Roel A Ophoff, Olli Pietiläinen, Leena Peltonen, Markus M Nöthen, Dan Rujescu, David St Clair, David A Collier, Ole A Andreassen, Thomas Werge.   

Abstract

BACKGROUND: Schizophrenia is associated with increased risk of type II diabetes and metabolic disorders. However, it is unclear whether this comorbidity reflects shared genetic risk factors, at-risk lifestyle, or side effects of antipsychotic medication.
METHODS: Eleven known risk variants of type II diabetes were genotyped in patients with schizophrenia in a sample of 410 Danish patients, each matched with two healthy control subjects on sex, birth year, and month. Replication was carried out in a large multinational European sample of 4089 patients with schizophrenia and 17,597 controls (SGENE+) using Mantel-Haenszel test.
RESULTS: One type II diabetes at-risk allele located in TCF7L2, rs7903146 [T], was associated with schizophrenia in the discovery sample (p = .0052) and in the replication with an odds ratio of 1.07 (95% confidence interval 1.01-1.14, p = .033).
CONCLUSION: The association reported here with a well-known diabetes variant suggests that the observed comorbidity is partially caused by genetic risk variants. This study also demonstrates how genetic studies can successfully examine an epidemiologically derived hypothesis of comorbidity.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414605     DOI: 10.1016/j.biopsych.2011.01.031

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  46 in total

Review 1.  Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.

Authors:  M A Daniels; C Kan; D M Willmes; K Ismail; F Pistrosch; D Hopkins; G Mingrone; S R Bornstein; A L Birkenfeld
Journal:  Pharmacogenomics J       Date:  2016-07-19       Impact factor: 3.550

2.  Bayesian semiparametric copula estimation with application to psychiatric genetics.

Authors:  Ori Rosen; Wesley K Thompson
Journal:  Biom J       Date:  2015-02-09       Impact factor: 2.207

Review 3.  Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.

Authors:  Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-06       Impact factor: 3.568

4.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

5.  In vitro scan for enhancers at the TCF7L2 locus.

Authors:  D Savic; S Y Park; K A Bailey; G I Bell; M A Nobrega
Journal:  Diabetologia       Date:  2012-09-26       Impact factor: 10.122

Review 6.  Wnt signaling and the control of human stem cell fate.

Authors:  J K Van Camp; S Beckers; D Zegers; W Van Hul
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

7.  Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives.

Authors:  Jaya L Padmanabhan; Pranav Nanda; Neeraj Tandon; Suraj S Mothi; Nicolas Bolo; Steven McCarroll; Brett A Clementz; Elliot S Gershon; Godfrey D Pearlson; John A Sweeney; Carol A Tamminga; Matcheri S Keshavan
Journal:  J Psychiatr Res       Date:  2016-02-23       Impact factor: 4.791

8.  Genetic association study between the detected risk variants based upon type II diabetes GWAS and psychotic disorders in the Japanese population.

Authors:  Yusuke Kajio; Kenji Kondo; Takeo Saito; Yoshimi Iwayama; Branko Aleksic; Kazuo Yamada; Tomoko Toyota; Eiji Hattori; Hiroshi Ujike; Toshiya Inada; Hiroshi Kunugi; Tadafumi Kato; Takeo Yoshikawa; Norio Ozaki; Masashi Ikeda; Nakao Iwata
Journal:  J Hum Genet       Date:  2013-11-07       Impact factor: 3.172

9.  Genetic Background Limits Generalizability of Genotype-Phenotype Relationships.

Authors:  Laura J Sittig; Peter Carbonetto; Kyle A Engel; Kathleen S Krauss; Camila M Barrios-Camacho; Abraham A Palmer
Journal:  Neuron       Date:  2016-09-08       Impact factor: 17.173

10.  The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Psychopharmacol       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.